Frederik Verelst

Waver, VLG, Belgium

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications

Cost-effectiveness of the adjuvanted respiratory syncytial virus prefusion F protein (RSVPreF3) vaccine in Japanese adults aged 50-59 years at increased risk of severe RSV disease and those aged ≥60 years.

Cost-effectiveness of the adjuvanted respiratory syncytial virus prefusion F protein (RSVPreF3) vaccine in Japanese adults aged 50-59 years at increased risk of severe RSV disease and those aged ≥60 years.

Journal: Expert review of vaccines
Published: February 04, 2026

Public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination among US adults aged 18-49 years at increased risk for severe RSV disease.

Public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination among US adults aged 18-49 years at increased risk for severe RSV disease.

Journal: Vaccine
Published: December 12, 2025

Health-related quality of life in European older adults with respiratory syncytial virus over three respiratory syncytial virus seasons.

Health-related quality of life in European older adults with respiratory syncytial virus over three respiratory syncytial virus seasons.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: October 03, 2025

Burden of Respiratory Syncytial Virus Among Older Adults With an Acute Respiratory Infection: A Prospective Study in Six European Countries.

Burden of Respiratory Syncytial Virus Among Older Adults With an Acute Respiratory Infection: A Prospective Study in Six European Countries.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: October 03, 2025

Burden of respiratory syncytial virus among older adults with an acute respiratory infection: a prospective study in six European countries.

Burden of respiratory syncytial virus among older adults with an acute respiratory infection: a prospective study in six European countries.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: October 03, 2025

Health-related Quality of Life in European Older Adults with Respiratory Syncytial Virus Over Three Respiratory Syncytial Virus Seasons.

Health-related Quality of Life in European Older Adults with Respiratory Syncytial Virus Over Three Respiratory Syncytial Virus Seasons.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: October 03, 2025

Two decades of GSK rotavirus vaccine (RV1): a global analysis to estimate vaccination completion and deaths averted in children under 5 years.

Two decades of GSK rotavirus vaccine (RV1): a global analysis to estimate vaccination completion and deaths averted in children under 5 years.

Journal: Expert review of vaccines
Published: September 22, 2025

Public health impact of RSV vaccination among adults aged 60 years and older in the United States using real-world evidence from the initial post-introduction season.

Public health impact of RSV vaccination among adults aged 60 years and older in the United States using real-world evidence from the initial post-introduction season.

Journal: Expert review of vaccines
Published: July 28, 2025

Public Health Impact and Cost-Effectiveness of Adjuvanted RSVPreF3 Vaccination among Adults in the USA Aged 50-59 Years at Increased Risk of Severe RSV Disease.

Public Health Impact and Cost-Effectiveness of Adjuvanted RSVPreF3 Vaccination among Adults in the USA Aged 50-59 Years at Increased Risk of Severe RSV Disease.

Journal: Infectious diseases and therapy
Published: July 09, 2025

Market and Non-Market Productivity Losses Associated with Invasive Meningococcal Disease in the USA.

Market and Non-Market Productivity Losses Associated with Invasive Meningococcal Disease in the USA.

Journal: PharmacoEconomics
Published: February 03, 2025

Older adults' and physicians' preferences for respiratory syncytial virus vaccination in Germany and Italy: A discrete choice experiment.

Older adults' and physicians' preferences for respiratory syncytial virus vaccination in Germany and Italy: A discrete choice experiment.

Journal: Vaccine
Published: January 13, 2025

Physician knowledge, attitudes, and perceptions of respiratory syncytial virus in older adults: A cross-sectional survey in Germany and Italy.

Physician knowledge, attitudes, and perceptions of respiratory syncytial virus in older adults: A cross-sectional survey in Germany and Italy.

Journal: PloS one
Published: January 03, 2025
Showing 1-12 of 33

Last Updated: 09/26/2026